Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

1. Pabst, T.
2. Papayannidis, C.
3. Demirkan, F.
4. Doronin, V.
5. Fogliatto, L.M.
6. Guttke, C.
7. Gyan, E.
8. Hamad, N.
9. Herrera, P.
10. Hultberg, A.
11. Jacobs, J.
12. Johnson, A.J.
13. Langlois, A.
14. Ma, X.
15. Martinelli, G.
16. Arnan, M.
17. Müller, R.
18. Nottage, K.
19. Ofran, Y.
20. Özcan, M.
21. Samoilova, O.
22. Tolbert, J.A.
23. Trudel, G.C.
24. Xiu, L.
25. Vey, N.
26. Wei, A.H.
27. Montrer des auteurs +